Inhibitor Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Selling, General & Admin	1.73	1.9	2.02	0.65	0.32	Upgrade
Research & Development	1.7	1.76	1.38	0.01	0	Upgrade
Operating Expenses	3.43	3.66	3.4	0.66	0.33	Upgrade
Operating Income	-3.43	-3.66	-3.4	-0.66	-0.33	Upgrade
Interest Expense	-	-	-	-0.02	-0.01	Upgrade
Interest & Investment Income	0.13	0.32	0.38	-	-	Upgrade
EBT Excluding Unusual Items	-3.3	-3.34	-3.03	-0.68	-0.34	Upgrade
Legal Settlements	-	-	-	12.62	-	Upgrade
Other Unusual Items	-	-	-	0.22	0.04	Upgrade
Pretax Income	-3.3	-3.34	-3.03	12.16	-0.3	Upgrade
Income Tax Expense	-	-	-	0.06	-	Upgrade
Net Income	-3.3	-3.34	-3.03	12.11	-0.3	Upgrade
Preferred Dividends & Other Adjustments	-	-	-	0.19	0.2	Upgrade
Net Income to Common	-3.3	-3.34	-3.03	11.92	-0.5	Upgrade
Shares Outstanding (Basic)	173	172	172	366	376	Upgrade
Shares Outstanding (Diluted)	173	172	172	366	376	Upgrade
Shares Change (YoY)	0.14%	0.18%	-53.04%	-2.67%	1.16%	Upgrade
EPS (Basic)	-0.02	-0.02	-0.02	0.03	-0.00	Upgrade
EPS (Diluted)	-0.02	-0.02	-0.02	0.03	-0.00	Upgrade
EBIT	-3.43	-3.66	-3.4	-0.66	-0.33	Upgrade
Effective Tax Rate	-	-	-	0.45%	-	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.